Experimental antibody takes on childhood brain cancers
NCT ID NCT03389802
First seen Nov 01, 2025 · Last updated Jun 24, 2026 · Updated 40 times
Summary
This early-stage trial is testing an experimental drug called APX005M in 32 children with brain tumors that have come back or are hard to treat, including a type of brain stem glioma. The drug works by activating the immune system to attack cancer cells. The main goals are to find the safest dose and see what side effects occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDULLOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Children Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, 15224, United States
-
Children's Healthcare of Atlanta
Atlanta, Georgia, 30322, United States
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90026, United States
-
Childrens National Medical Center
Washington D.C., District of Columbia, 20010-2970, United States
-
Cincinnati Children Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Lucile Packard Children Hospital Stanford University
Palo Alto, California, 94304, United States
-
Lurie Childrens Hospital-Chicago
Chicago, Illinois, 60614, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
St. Jude Children Research Hospital
Memphis, Tennessee, 38105, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
APX005M (an experimental antibody that activates the immune system)
What this could lead to
If successful, this could point toward a new treatment option for children with hard-to-treat brain tumors.
What could go wrong
This is a very early Phase 1 trial with only 32 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or improve survival, and side effects like cytokine release syndrome are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.